TWI372625B - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors - Google Patents

Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

Info

Publication number: TWI372625B
Authority: TW; Taiwan
Prior art keywords: kinase inhibitors; dependent kinase; cyclin dependent; novel pyrazolopyrimidines; pyrazolopyrimidines
Prior art date: 2005-10-06

Application number

TW099120151A

Other languages

Chinese (zh)

Other versions

TW201038271A (en

Inventor

Kamil Paruch

Timothy J Guzi

Michael P Dwyer

Marc Labroli

Kartik M Keertikar

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-06

Filing date

2006-10-04

Publication date

2012-09-21

2006-10-04 Application filed by Schering Corp filed Critical Schering Corp

2010-11-01 Publication of TW201038271A publication Critical patent/TW201038271A/en

2012-09-21 Application granted granted Critical

2012-09-21 Publication of TWI372625B publication Critical patent/TWI372625B/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hematology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Powder Metallurgy (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

TW099120151A 2005-10-06 2006-10-04 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors TWI372625B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11/245,401 US7196078B2 (en)	2002-09-04	2005-10-06	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors

Publications (2)

Publication Number	Publication Date
TW201038271A TW201038271A (en)	2010-11-01
TWI372625B true TWI372625B (en)	2012-09-21

Family

ID=37866152

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TW095136814A TWI362263B (en)	2005-10-06	2006-10-04	Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW099120151A TWI372625B (en)	2005-10-06	2006-10-04	Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
TW095136814A TWI362263B (en)	2005-10-06	2006-10-04	Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

Country Status (20)

Country	Link
US (2)	US7196078B2 (en)
EP (1)	EP1931677B1 (en)
JP (2)	JP4925226B2 (en)
KR (2)	KR20080063796A (en)
CN (2)	CN102627645A (en)
AR (1)	AR056873A1 (en)
AU (1)	AU2006302443B2 (en)
BR (1)	BRPI0616987B1 (en)
CA (1)	CA2624829C (en)
EC (1)	ECSP088345A (en)
ES (1)	ES2574782T3 (en)
IL (2)	IL190510A (en)
MY (1)	MY162134A (en)
NO (1)	NO20082091L (en)
NZ (1)	NZ567187A (en)
PE (1)	PE20070496A1 (en)
RU (1)	RU2441005C2 (en)
TW (2)	TWI362263B (en)
WO (1)	WO2007044449A2 (en)
ZA (1)	ZA200802996B (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8673924B2 (en)	2002-09-04	2014-03-18	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) *	2002-09-04	2009-10-20	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196078B2 (en) *	2002-09-04	2007-03-27	Schering Corpoartion	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) *	2002-09-04	2009-07-21	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US8580782B2 (en) *	2002-09-04	2013-11-12	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
TWI421078B (en) *	2005-10-06	2014-01-01	Merck Sharp & Dohme	Checkpoint kinase inhibitors and use thereof
WO2008043077A2 (en) *	2006-10-05	2008-04-10	Jazwares, Inc.	Jigsaw puzzle display frame
MX2009005300A (en) *	2006-11-17	2009-06-08	Schering Corp	Combination therapy for proliferative disorders.
TW200845962A (en)	2007-05-08	2008-12-01	Schering Corp	Methods of treatment using intravenous formulations comprising temozolomide
EP2155725A1 (en) *	2007-06-07	2010-02-24	Schering Corporation	Synthesis of substituted-3-aminopyrazoles
WO2009123986A1 (en) *	2008-03-31	2009-10-08	Takeda Pharmaceutical Company Limited	Apoptosis signal-regulating kinase 1 inhibitors
PE20110063A1 (en) *	2008-06-20	2011-02-16	Genentech Inc	DERIVATIVES OF [1, 2, 4] TRIAZOLO [1, 5-a] PYRIDINE AS JAK INHIBITORS
CA2727036C (en)	2008-06-20	2017-03-21	Genentech, Inc.	Triazolopyridine jak inhibitor compounds and methods
US8450322B2 (en)	2008-09-22	2013-05-28	Array Biopharma Inc.	Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
KR102037619B1 (en)	2008-10-22	2019-10-28	어레이 바이오파마 인크.	SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
EP2417138B1 (en) *	2009-04-09	2019-11-27	Merck Sharp & Dohme Corp.	Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors
AU2015201984B2 (en) *	2009-07-09	2016-08-04	Array Biopharma Inc.	SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
AR077468A1 (en)	2009-07-09	2011-08-31	Array Biopharma Inc	PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
US8993535B2 (en)	2009-09-04	2015-03-31	Merck Sharp & Dohme Corp.	Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
US9062076B2 (en)	2009-10-22	2015-06-23	Fibrotech Therapeutics Pty Ltd	Fused ring analogues of anti-fibrotic agents
KR101478889B1 (en) *	2010-02-26	2015-01-02	미쓰비시 타나베 파마 코퍼레이션	Pyrazolopyrimidine compounds and their use as pde10 inhibitors
US8680271B2 (en)	2010-03-26	2014-03-25	Merck Sharp & Dohme Corp.	Process for synthesizing 6-bromo-3-1-(1-methyl-1H-pyrazol-4-yl)-5-(3(R)-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-amine
ES2628418T3 (en) *	2010-05-20	2017-08-02	Array Biopharma, Inc.	Macrocyclic compounds as inhibitors of TRK kinase
US20130196986A1 (en) *	2010-09-21	2013-08-01	Marc Labroli	Triazolopyrazinones as p2x7 receptor antagonists
FR2965262A1 (en)	2010-09-24	2012-03-30	Sanofi Aventis	NICOTINAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
US10953012B2 (en)	2011-04-26	2021-03-23	Bioenergenix Llc	Heterocyclic compounds for the inhibition of pask
WO2012178125A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EA030465B1 (en)	2011-07-01	2018-08-31	Новартис Аг	Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
US9345705B2 (en)	2011-09-15	2016-05-24	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
US9498471B2 (en)	2011-10-20	2016-11-22	The Regents Of The University Of California	Use of CDK9 inhibitors to reduce cartilage degradation
US10392389B2 (en)	2012-10-25	2019-08-27	Bioenergenix Llc	Heterocyclic compounds for the inhibition of PASK
WO2014066743A1 (en)	2012-10-25	2014-05-01	Bioenergenix	Heterocyclic compounds for the inhibition of pask
CN107501275B (en)	2012-12-07	2019-11-22	沃泰克斯药物股份有限公司	It can be used as the compound of ATR kinase inhibitor
SG11201505493QA (en)	2013-02-21	2015-08-28	Calitor Sciences Llc	Heteroaromatic compounds as pi3 kinase modulators
EP2970288A1 (en)	2013-03-15	2016-01-20	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
JP2016512239A (en)	2013-03-15	2016-04-25	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Compounds useful as inhibitors of ATR kinase
US9663519B2 (en)	2013-03-15	2017-05-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
PT3077397T (en)	2013-12-06	2020-01-22	Vertex Pharma	2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
JP6568111B2 (en)	2014-06-05	2019-08-28	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Radiolabeled derivatives of 2-amino-6-fluoro-N- [5-fluoro-pyridin-3-yl] pyrazolo [1,5-a] pyrimidine-3-carboxamide compounds useful as ATR kinase inhibitors, Preparation of compounds and their different solid forms
HRP20191375T1 (en)	2014-06-17	2019-11-01	Vertex Pharma	Method for treating cancer using a combination of chk1 and atr inhibitors
EP3206749B1 (en)	2014-10-14	2021-09-08	The Regents of the University of California	The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
CA2967951C (en)	2014-11-16	2023-11-07	Array Biopharma, Inc.	Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10550121B2 (en) *	2015-03-27	2020-02-04	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
GB201517263D0 (en) *	2015-09-30	2015-11-11	Ucb Biopharma Sprl And Katholieke Universiteit Leuven	Therapeutic agents
RU2768621C1 (en)	2015-09-30	2022-03-24	Вертекс Фармасьютикалз Инкорпорейтед	Method of treating cancer using a combination of dna damaging agents and atr inhibitors
CN108697708A (en)	2015-10-26	2018-10-23	洛克索肿瘤学股份有限公司	Point mutation in TRK inhibitor resistant cancers and method related to this
EP3377908B1 (en)	2015-11-18	2020-08-05	Genzyme Corporation	Biomarker of polycystic kidney disease and uses thereof
RU2619932C1 (en) *	2015-11-25	2017-05-22	федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ")	SUBSTITUTED PYRAZOLO[1.5-a]PYRIDO[3.4-e]PYRIMIDINES AND THEIR USE AS PROTEINQUINASE INHIBITORS
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
SI3439662T1 (en)	2016-04-04	2024-11-29	Loxo Oncology, Inc.	Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
DK3458456T3 (en)	2016-05-18	2020-12-14	Array Biopharma Inc	PREPARATION OF (S) -N- (5 - ((R) -2- (2,5-DIFLUOROPHENYL) PYRROLIDIN-1-YL) PYRAZOLE [1,5-A] PYRIMIDIN-3-YL) -3-HYDROXYPYRROLIDIN- 1-CARBOXAMID
JP7471818B2 (en)	2016-08-18	2024-04-22	ヴィダックファーマリミテッド	Piperazine derivatives, pharmaceutical compositions, and methods of use thereof
JOP20190092A1 (en)	2016-10-26	2019-04-25	Array Biopharma Inc	PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
SG11201907139UA (en)	2017-02-03	2019-09-27	Certa Therapeutics Pty Ltd	Anti-fibrotic compounds
JOP20190213A1 (en)	2017-03-16	2019-09-16	Array Biopharma Inc	Macrocyclic compounds as ros1 kinase inhibitors
PT3658557T (en)	2017-07-28	2024-09-11	Nimbus Lakshmi Inc	TYK2 INHIBITORS AND THEIR USES
EP3461480A1 (en)	2017-09-27	2019-04-03	Onxeo	Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CA3079848A1 (en)	2017-11-07	2019-05-16	The Regents Of The University Of Michigan	Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
AU2019360941B2 (en) *	2018-10-15	2025-02-27	Takeda Pharmaceutical Company Limited	TYK2 inhibitors and uses thereof
MD20210033A2 (en) *	2018-10-30	2021-10-31	Kronos Bio, Inc.	Compounds, compositions and methods for modulating CDK9 activity
SG11202110523XA (en)	2019-03-26	2021-10-28	Ventyx Biosciences Inc	Tyk2 pseudokinase ligands
AU2020378345A1 (en)	2019-11-08	2022-06-02	Ventyx Biosciences, Inc.	TYK2 pseudokinase ligands
WO2024151112A1 (en) *	2023-01-11	2024-07-18	주식회사 티움바이오	Pyrazolopyrimidine derivative as cyclin-dependent kinase 9 inhibitor
KR20240168242A (en) *	2023-05-22	2024-11-29	주식회사 셀러스	Novel CDK7 inhibitory compounds and uses thereof
CN119707984A (en) *	2023-09-28	2025-03-28	中国科学院上海药物研究所	Pyrazolotriazine and pyrazolopyrimidine derivative, preparation method thereof, pharmaceutical composition and application thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0591528B1 (en) *	1991-04-22	1998-12-23	Otsuka Pharmaceutical Factory, Inc.	PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
EP0628559B1 (en)	1993-06-10	2002-04-03	Beiersdorf-Lilly GmbH	Pyrimidine compounds and their use as pharmaceuticals
US5571813A (en) *	1993-06-10	1996-11-05	Beiersdorf-Lilly Gmbh	Fused pyrimidine compounds and their use as pharmaceuticals
EP0714898B1 (en)	1994-06-21	2001-11-14	Otsuka Pharmaceutical Factory, Inc.	PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE
US5919815A (en) *	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
US6313124B1 (en) *	1997-07-23	2001-11-06	Dupont Pharmaceuticals Company	Tetrazine bicyclic compounds
US6191131B1 (en) *	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
US6040321A (en) *	1997-11-12	2000-03-21	Bristol-Myers Squibb Company	Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) *	1997-11-12	2001-07-17	Bristol-Myers Squibb Company	Aminothiazole inhibitors of cyclin dependent kinases
AU747705C (en) *	1997-12-13	2004-09-23	Bristol-Myers Squibb Company	Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors
US6413974B1 (en) *	1998-02-26	2002-07-02	Aventis Pharmaceuticals Inc.	6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6194410B1 (en) *	1998-03-11	2001-02-27	Hoffman-La Roche Inc.	Pyrazolopyrimidine and pyrazolines and process for preparation thereof
OA12049A (en)	1999-09-30	2006-05-02	Neurogen Corp	Amino substituted pyrazoloÄ1,5,-aÜ-1,5-pyrimidinesand pyrazoloÄ1,5,-aÜ-1,3,5-triazines.
NZ525016A (en)	2000-09-15	2004-10-29	Vertex Pharma	Isoxazoles and their use as inhibitors of ERK
US7067520B2 (en)	2000-11-17	2006-06-27	Ishihara Sangyo Kaisha, Ltd.	Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
CA2432417A1 (en)	2000-12-20	2002-06-27	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.)	Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors
EP1505068A4 (en)	2002-04-23	2008-03-19	Shionogi & Co	PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
ES2287476T3 (en)	2002-05-10	2007-12-16	Smithkline Beecham Corporation	REPLACED PIRAZOLOPIRIMIDINAS.
DE10223917A1 (en)	2002-05-29	2003-12-11	Bayer Cropscience Ag	New 7-amino-6-aryl-pyrazolo-(1,5-a)-pyrimidine derivatives, useful as pesticides, e.g. insecticides, acaricides, nematocides, bactericides or especially fungicides for protection of plants or materials
ES2291665T3 (en) *	2002-09-04	2008-03-01	Schering Corporation	PIRAZOLOPIRIMIDINAS AS INHIBITORS OF CYCLINE-DEPENDENT KINASES.
US7119200B2 (en) *	2002-09-04	2006-10-10	Schering Corporation	Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) *	2002-09-04	2007-03-27	Schering Corpoartion	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2497440C (en)	2002-09-04	2011-03-22	Schering Corporation	Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
CA2497539A1 (en) *	2002-09-04	2004-03-18	Schering Corporation	Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0305559D0 (en)	2003-03-11	2003-04-16	Teijin Ltd	Compounds
US20070179161A1 (en)	2003-03-31	2007-08-02	Vernalis (Cambridge) Limited.	Pyrazolopyrimidine compounds and their use in medicine
CA2539320A1 (en)	2003-09-17	2005-03-31	Icos Corporation	Use of chk1 inhibitors to control cell proliferation
AR049769A1 (en)	2004-01-22	2006-09-06	Novartis Ag	DERIVATIVES OF PIRAZOLO (1,5-A) PIRIMIDIN 7-IL-AMINA TO BE USED IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE
US20050222171A1 (en) *	2004-01-22	2005-10-06	Guido Bold	Organic compounds
US7288124B2 (en) *	2004-09-08	2007-10-30	L'oreal S.A.	Heteroaromatic binuclear black direct dyes
GB0519957D0 (en)	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
JP2008524330A (en) *	2004-12-21	2008-07-10	シェーリングコーポレイション	Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonist

2005
- 2005-10-06 US US11/245,401 patent/US7196078B2/en not_active Expired - Lifetime
2006
- 2006-10-04 MY MYPI20080984A patent/MY162134A/en unknown
- 2006-10-04 BR BRPI0616987-2A patent/BRPI0616987B1/en active IP Right Grant
- 2006-10-04 WO PCT/US2006/038939 patent/WO2007044449A2/en not_active Ceased
- 2006-10-04 TW TW095136814A patent/TWI362263B/en not_active IP Right Cessation
- 2006-10-04 AU AU2006302443A patent/AU2006302443B2/en active Active
- 2006-10-04 CA CA2624829A patent/CA2624829C/en active Active
- 2006-10-04 AR ARP060104369A patent/AR056873A1/en not_active Application Discontinuation
- 2006-10-04 PE PE2006001207A patent/PE20070496A1/en not_active Application Discontinuation
- 2006-10-04 NZ NZ567187A patent/NZ567187A/en not_active IP Right Cessation
- 2006-10-04 ES ES06836186.4T patent/ES2574782T3/en active Active
- 2006-10-04 RU RU2008117295/04A patent/RU2441005C2/en active
- 2006-10-04 TW TW099120151A patent/TWI372625B/en not_active IP Right Cessation
- 2006-10-04 CN CN2012100567677A patent/CN102627645A/en active Pending
- 2006-10-04 KR KR1020087010183A patent/KR20080063796A/en not_active Ceased
- 2006-10-04 JP JP2008534679A patent/JP4925226B2/en active Active
- 2006-10-04 KR KR1020147018349A patent/KR101661405B1/en active Active
- 2006-10-04 CN CNA2006800453382A patent/CN101321756A/en active Pending
- 2006-10-04 EP EP06836186.4A patent/EP1931677B1/en active Active
2007
- 2007-02-23 US US11/710,644 patent/US8586576B2/en not_active Expired - Fee Related
2008
- 2008-03-30 IL IL190510A patent/IL190510A/en active IP Right Grant
- 2008-04-04 ZA ZA200802996A patent/ZA200802996B/en unknown
- 2008-04-04 EC EC2008008345A patent/ECSP088345A/en unknown
- 2008-05-05 NO NO20082091A patent/NO20082091L/en not_active Application Discontinuation
2011
- 2011-10-25 IL IL215929A patent/IL215929A0/en unknown
2012
- 2012-01-11 JP JP2012003526A patent/JP2012072189A/en not_active Withdrawn

Also Published As

Publication number	Publication date
ECSP088345A (en)	2008-05-30
US20060128725A1 (en)	2006-06-15
ES2574782T3 (en)	2016-06-22
TW200800224A (en)	2008-01-01
TWI362263B (en)	2012-04-21
EP1931677B1 (en)	2016-04-20
BRPI0616987B1 (en)	2021-08-31
KR20140097558A (en)	2014-08-06
CA2624829A1 (en)	2007-04-19
EP1931677A2 (en)	2008-06-18
US7196078B2 (en)	2007-03-27
JP4925226B2 (en)	2012-04-25
NZ567187A (en)	2011-09-30
IL190510A (en)	2014-02-27
ZA200802996B (en)	2009-03-25
CN101321756A (en)	2008-12-10
US20070225270A1 (en)	2007-09-27
AU2006302443A1 (en)	2007-04-19
MY162134A (en)	2017-05-31
CA2624829C (en)	2014-05-27
JP2012072189A (en)	2012-04-12
IL215929A0 (en)	2011-12-29
KR101661405B1 (en)	2016-09-29
TW201038271A (en)	2010-11-01
AR056873A1 (en)	2007-10-31
NO20082091L (en)	2008-07-04
AU2006302443B2 (en)	2012-07-26
BRPI0616987A2 (en)	2009-08-04
KR20080063796A (en)	2008-07-07
WO2007044449A3 (en)	2007-05-24
IL190510A0 (en)	2008-11-03
WO2007044449A2 (en)	2007-04-19
JP2009511487A (en)	2009-03-19
PE20070496A1 (en)	2007-07-13
US8586576B2 (en)	2013-11-19
RU2008117295A (en)	2009-11-20
RU2441005C2 (en)	2012-01-27
CN102627645A (en)	2012-08-08

Publication	Publication Date	Title
TWI372625B (en)	2012-09-21	Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
IL177283A0 (en)	2006-12-10	Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
IL190598A0 (en)	2008-11-03	Pyrazolopyrimidines as protein kinase inhibitors
IL191294A0 (en)	2009-02-11	Imidazopyrazines as protein kinase inhibitors
IL177278A0 (en)	2006-12-10	Pyrazolotriazines as kinase inhibitors
ZA200900109B (en)	2010-03-31	Pyrrolotriazine kinase inhibitors
IL190078A0 (en)	2008-08-07	Kinase inhibitors
EP1761268A4 (en)	2009-07-08	Pyrrolotriazine kinase inhibitors
IL184674A0 (en)	2007-12-03	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
IL187310A0 (en)	2008-04-13	Bicyclic derivatives as p38 kinase inhibitors
EP1773837A4 (en)	2009-07-15	Pyrrolotriazine kinase inhibitors
IL188027A0 (en)	2008-03-20	Bicyclic derivatives as p38 kinase inhibitors
PL1943243T3 (en)	2011-05-31	Kinase inhibitors
EP1778693A4 (en)	2009-11-11	Tricyclic-heteroaryl compounds useful as kinase inhibitors
HK1116785A (en)	2009-01-02	Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
HK1126764A (en)	2009-09-11	Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
HK1126765A (en)	2009-09-11	Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
HK1112624A (en)	2008-09-12	Imidazopyrazines as cyclin dependent kinase inhibitors
HK1126763A (en)	2009-09-11	Pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1940411A4 (en)	2008-10-29	Macroheterocylic compounds as kinase inhibitors
HK1112740A (en)	2008-09-12	Pyrazolopyrimidines as protein kinase inhibitors
HK1112234A (en)	2008-08-29	Pyrazolopyrimidines as protein kinase inhibitors
IL189985A0 (en)	2008-08-07	Kinase inhibitors
ZA200803287B (en)	2009-10-28	Kinase inhibitors
ZA200706212B (en)	2008-06-25	Pyrazolylaminopyridine derivatives useful as kinase inhibitors

Legal Events

Date	Code	Title	Description
2015-06-21	MM4A	Annulment or lapse of patent due to non-payment of fees